Adult: 10 mg once daily or 5 mg bid. Child: 2-12 years ≤30 kg: 5 mg once daily; >30 kg: 10 mg once daily. >12 years Same as adult dose. Dosage recommendations may vary among individual products or between countries (refer to detailed product guideline).
Renal Impairment
CrCl (mL/min)
Dosage
<30
10 mg every other day.
Hepatic Impairment
Severe: Initially, 10 mg every other day. Alternatively, initial dose of 5 mg once daily may be given.
Administration
May be taken with or without food.
Special Precautions
Severe hepatic and renal impairment. Children. Pregnancy and lactation.
Adverse Reactions
Cardiac disorders: Very rarely, tachycardia, palpitation. Gastrointestinal disorders: Very rarely, nausea, dry mouth, gastritis. General disorders and administration site conditions: Fatigue (mainly in children). Hepatobiliary disorders: Very rarely, abnormal hepatic function. Immune system disorders: Very rarely, hypersensitivity reactions, including anaphylaxis and angioedema. Investigations: Increased weight. Metabolism and nutrition disorders: Increased appetite. Nervous system disorders: Headache, drowsiness. Very rarely, dizziness, convulsion. Psychiatric disorders: Insomnia; nervousness (mainly in children). Skin and subcutaneous tissue disorders: Very rarely, rash, alopecia.
Patient Counseling Information
This drug may cause drowsiness, if affected, do not drive or operate machinery.
Overdosage
Symptoms: Somnolence, headache, and tachycardia. Management: Symptomatic and supportive treatment. Consider administration of activated charcoal or performing gastric lavage.
Drug Interactions
Plasma concentration may be increased by CYP3A4 or CYP2D6 inhibitors (e.g. ketoconazole, erythromycin, cimetidine).
Food Interaction
Food delays time to peak plasma concentrations and increases bioavailability. May increase the CNS depressant effects of alcohol.
Lab Interference
May diminish the wheal and flare reactions to skin test antigens.
Action
Description: Loratadine, a piperidine derivative, is a long-acting, non-sedating tricyclic antihistamine with no significant antimuscarinic properties. It exhibits a competitive and selective peripheral H1-receptor antagonistic activity. Onset: 1-3 hours. Duration: >24 hours. Pharmacokinetics: Absorption: Rapidly and well absorbed from the gastrointestinal tract. Food delays time to peak plasma concentration and increases bioavailability. Time to peak plasma concentration: 1-1.5 hours (loratadine); 1.5-3.7 hours (desloratadine). Distribution: Enters breast milk. Volume of distribution: 119 L/kg. Plasma protein binding: 97-99% (loratadine); 73-76% (desloratadine). Metabolism: Extensively metabolised in the liver mainly by CYP2D6 and CYP3A4 isoenzymes to form the major active metabolite, desloratadine (descarboethoxyloratadine). Undergoes first-pass metabolism. Excretion: Via urine (approx 40%) and faeces (42%), mainly as metabolites. Elimination half-life: Loratadine: 8.4 hours (range: 3-20 hours). Desloratadine: 28 hours (range: 8.8-92 hours).
Chemical Structure
Loratadine Source: National Center for Biotechnology Information. PubChem Compound Summary for CID 3957, Loratadine. https://pubchem.ncbi.nlm.nih.gov/compound/3957. Accessed July 26, 2022.
Storage
Store below 30°C. Protect from moisture. Storage recommendations may vary among individual products or between countries (refer to detailed product guideline).
Sign Out
